Mircera Clinical Applications and Safety

Adverse Effects and Clinical Considerations

• The National Kidney Foundation recommends assessing iron status and ensuring adequate iron stores before initiating Mircera therapy, with intravenous iron supplementation often necessary alongside ESA therapy in CKD patients 3, 4
• The American Society of Hematology suggests target hemoglobin levels should be individualized based on clinical circumstances, with most guidelines recommending maintaining hemoglobin between 10-12 g/dL, and careful monitoring is required in patients with risk factors for thromboembolism 5
• Common side effects of Mircera include headache and pain at injection site, according to the Journal of Hepatology 1
• Rare but serious potential adverse effects of Mircera include thrombotic events and pure red cell aplasia, as reported in the Annals of Oncology 2